Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (MPRvsMEL200)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus
ClinicalTrials.gov Identifier:
NCT00551928
First received: October 30, 2007
Last updated: May 9, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2019
  Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):